Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
COMMENT AND RESPONSE

Time for a strategic research response to anal cancer

Andrew E. Grulich A F , Richard Hillman A B , Julia M. L. Brotherton C D and Christopher K. Fairley D E
+ Author Affiliations
- Author Affiliations

A Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.

B Centre of Infectious Diseases and Microbiology-Sexual Health, University of Sydney, Sydney, NSW 2006, Australia.

C Victorian Cytology Service, East Melbourne, Vic. 3002, Australia.

D School of Population Health, University of Melbourne, Melbourne, Vic. 3010, Australia.

E Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic. 3010, Australia.

F Corresponding author. Email: agrulich@kirby.unsw.edu.au

Sexual Health 9(6) 628-631 https://doi.org/10.1071/SH12116
Submitted: 23 July 2012  Accepted: 30 October 2012   Published: 27 November 2012

Abstract

Anal cancer was until recently regarded as a rare cancer of little consequence. The articles in this special edition of Sexual Health clearly demonstrate that anal cancer is increasing in incidence and, in some populations, it has become an urgent public health priority. In this summary paper, we will review the data presented in this issue and elsewhere on the magnitude of the issue, the means of prevention and treatment, and suggest a way forward.

Additional keywords: human papillomavirus, incidence, prevalence, prevention, screening, treatment.


References

[1]  Machalek DA, Grulich AE, Jin F, Templeton DJ, Poynten IM. The epidemiology and natural history of anal HPV infection in men who have sex with men. Sex Health 2012; 9 527–537.

[2]  Machalek DA, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, et al Anal human papillomavirus infection, and associated neoplastic lesions in homosexual men: systematic review and meta-analysis. Lancet Oncol 2012; 13 487–500.
Anal human papillomavirus infection, and associated neoplastic lesions in homosexual men: systematic review and meta-analysis.CrossRef |

[3]  Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, et al Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008; 197 957–66.
Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study.CrossRef |

[4]  Nyitray AG. The epidemiology of anal human papillomavirus infection among women and men having sex with women. Sex Health 2012; 9 538–546.
The epidemiology of anal human papillomavirus infection among women and men having sex with women.CrossRef |

[5]  Richters J, Grulich AE, de Visser RO, Smith AM, Rissel CE. Sex in Australia: autoerotic, esoteric and other sexual practices engaged in by a representative sample of adults. Aust N Z J Public Health 2003; 27 180–90.
Sex in Australia: autoerotic, esoteric and other sexual practices engaged in by a representative sample of adults.CrossRef |

[6]  Jin F, Prestage GP, Kippax SC, Pell CM, Donovan B, Templeton DJ, et al Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007; 34 488–93.

[7]  Coutlée F, de Pokomandy A, Franco EL. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex Health 2012; 9 547–555.

[8]  Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health 2012; 9 504–508.
The epidemiology of anal cancer.CrossRef |

[9]  Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365 1576–85.
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.CrossRef | 1:CAS:528:DC%2BC3MXhsVSrsrbN&md5=5aa2abd713524740622154793fcda290CAS |

[10]  Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial. Lancet Oncol 2011; 12 862–70.
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial.CrossRef | 1:CAS:528:DC%2BC3MXhtFSqs7%2FF&md5=d553b65b3a0675b65f86fc4eeda27e54CAS |

[11]  Department of Health and Ageing (DoHA). Immunise Australia program. Canberra: DoHA; 2012. Available online at: www.immunise.health.gov.au [verified July 2012].

[12]  Dunne EFML, Chesson H, Curtis CR, Saraiya M, Gee J, Unger ER. Recommendations on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60 1705–8.

[13]  Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 415–22.
Anal cytology as a screening tool for anal squamous intraepithelial lesions.CrossRef | 1:STN:280:DyaK2szhsVSksQ%3D%3D&md5=843dc3a3960718701c4eb9321b89291cCAS |

[14]  Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113 18–25.

[15]  McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9 425–34.
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.CrossRef |

[16]  Roberts JM, Thurloe JK. Comparison of the performance of anal cytology and cervical cytology as screening tests. Sex Health 2012; 9 568–573.
Comparison of the performance of anal cytology and cervical cytology as screening tests.CrossRef |

[17]  Palefsky JM. Practicing high-resolution anoscopy. Sex Health 2012; 9 580–586.

[18]  Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197 356 e1–6.
Risk assessment to guide the prevention of cervical cancer.CrossRef |

[19]  Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197 340–5.
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.CrossRef |

[20]  Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007; 11 223–39.
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.CrossRef |

[21]  Poynten IM, Templeton DJ, Grulich AE. Sexually transmissible infections in aging HIV populations. Sex Health 2011; 8 508–11.
Sexually transmissible infections in aging HIV populations.CrossRef |

[22]  Fox PA. Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness. Sex Health 2012; 9 587–592.
Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness.CrossRef |

[23]  Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367 489–98.
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis.CrossRef | 1:STN:280:DC%2BD28%2FoslCmtQ%3D%3D&md5=0dc644f6576f5cadd0522534e2b60dd2CAS |

[24]  Chamot E, Kristensen S, Stringer JS, Mwanahamuntu MH. Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC Womens Health 2010; 10 11
Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review.CrossRef |

[25]  Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 1–207.

[26]  Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010; 37 202–15.
Principles of cancer screening: lessons from history and study design issues.CrossRef |

[27]  Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64 1263–72.
| 1:STN:280:DyaL3c7mtlKgsg%3D%3D&md5=fcf3c0e48401a9061c960900ad6b2a83CAS |

[28]  Smith DP, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189 315–8.

[29]  Hoffman RM. Randomized trial results did not resolve controversies surrounding prostate cancer screening. Curr Opin Urol 2010; 20 189–93.
Randomized trial results did not resolve controversies surrounding prostate cancer screening.CrossRef |

[30]  Brawley OW. Prostate cancer screening; is this a teachable moment? J Natl Cancer Inst 2009; 101 1295–7.
Prostate cancer screening; is this a teachable moment?CrossRef |

[31]  Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157 120–34.

[32]  Howard K. The cost-effectiveness of screening for anal cancer in men who have sex with men: a systematic review. Sex Health 2012; 9 610–619.
The cost-effectiveness of screening for anal cancer in men who have sex with men: a systematic review.CrossRef |



Rent Article (via Deepdyve) Export Citation Cited By (7)